Literature DB >> 2245965

Measurement of urinary growth hormone. A noninvasive method to assess the 'growth hormone status'.

J Girard1, T Fischer-Wasels.   

Abstract

Using pharmacological tests or GH profiles, GH deficiency or active acromegaly can be diagnosed. However, it is impossible to discriminate within the continuum between 'deficiency/insufficiency' and 'sufficient secretion'. The use of GH to improve growth velocity is based on 1 injection once a day. It is thus the total amount of GH which appears to be important for its growth-promoting effect. An assay of GH in urine allows to assess such GH 'production', even over a prolonged period of time. A radiometric two-step assay applicable to untreated urine is presented. Results for assessing the 'GH status' by measuring GH in 24-hour urine, first morning-void urine or timed urine samples are shown. The correlation between 24-hour plasma profiles and the simultaneously collected 24-hour urine is significant at p less than 0.01. A correlation coefficient greater than 0.9 was found between timed urine samples (4 h) and the 120-min plasma GH values during GHRH stimulation tests. The night-to-night variation of urinary GH can be very important. It is advisable, therefore, to use the mean of several night urines. The correlation between the mean urinary GH of 5 nights to one 24-hour sample is significant at p less than 0.01. An age-dependent increase in urinary GH is found in the pubertal age group.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2245965     DOI: 10.1159/000181578

Source DB:  PubMed          Journal:  Horm Res        ISSN: 0301-0163


  6 in total

Review 1.  Screening tests for growth hormone deficiency.

Authors:  A J Evans
Journal:  J R Soc Med       Date:  1995-03       Impact factor: 5.344

Review 2.  Nanoparticle technology: amplifying the effective sensitivity of biomarker detection to create a urine test for hGH.

Authors:  Claudia Fredolini; Davide Tamburro; Guido Gambara; Benjamin S Lepene; Virginia Espina; Emanuel F Petricoin; Lance A Liotta; Alessandra Luchini
Journal:  Drug Test Anal       Date:  2009-09       Impact factor: 3.345

3.  Effects of arginine treatment on nutrition, growth and urea cycle function in seven Japanese boys with late-onset ornithine transcarbamylase deficiency.

Authors:  Hironori Nagasaka; Tohru Yorifuji; Kei Murayama; Mitsuru Kubota; Keiji Kurokawa; Tomoko Murakami; Masaki Kanazawa; Tomozumi Takatani; Atsushi Ogawa; Emi Ogawa; Shigenori Yamamoto; Masanori Adachi; Kunihiko Kobayashi; Masaki Takayanagi
Journal:  Eur J Pediatr       Date:  2006-05-16       Impact factor: 3.183

4.  Relationship between urinary and serum growth hormone and pubertal status.

Authors:  E C Crowne; W H Wallace; S M Shalet; G M Addison; D A Price
Journal:  Arch Dis Child       Date:  1992-01       Impact factor: 3.791

5.  Growth hormone and insulin-like growth factor-1 in blood and urine as response markers during treatment of acromegaly with octreotide: a double-blind placebo-controlled study.

Authors:  L Fredstorp; S Werner
Journal:  J Endocrinol Invest       Date:  1993-04       Impact factor: 4.256

6.  Microencapsulated octreotide pamoate in advanced gastrointestinal and pancreatic cancer: a phase I study.

Authors:  S I Helle; J Geisler; J P Poulsen; K Hestdal; K Meadows; W Collins; K M Tveit; J M Holly; P E Lønning
Journal:  Br J Cancer       Date:  1998-07       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.